Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 14.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 305,341 shares of the specialty pharmaceutical company’s stock after selling 51,621 shares during the quarter. Victory Capital Management Inc. owned about 0.50% of Jazz Pharmaceuticals worth $40,244,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada grew its position in Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after buying an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after buying an additional 7,954 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after acquiring an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on JAZZ shares. Piper Sandler reiterated an “overweight” rating and set a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Barclays initiated coverage on Jazz Pharmaceuticals in a research report on Friday, February 27th. They issued an “overweight” rating and a $224.00 target price for the company. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Bank of America boosted their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, UBS Group restated a “neutral” rating and issued a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $214.57.

Jazz Pharmaceuticals Stock Down 0.9%

JAZZ stock opened at $182.01 on Friday. The firm has a market cap of $11.20 billion, a PE ratio of -30.49, a P/E/G ratio of 0.36 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $198.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. The firm has a 50 day simple moving average of $171.11 and a 200 day simple moving average of $154.08.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.51 earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,253 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $194.11, for a total value of $243,219.83. Following the completion of the transaction, the chief accounting officer owned 10,352 shares in the company, valued at $2,009,426.72. This trade represents a 10.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the transaction, the senior vice president directly owned 28,728 shares in the company, valued at $5,587,308.72. This represents a 15.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 68,966 shares of company stock valued at $13,181,406. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.